Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma

Cancer Genetics and Cytogenetics

Volumn 190, Issue 2, 2009, Pages 66-70

  Bruchim, Ilan ^a   Israeli, Ofir ^b   Mahmud, Salaheddin M ^c   Aviram Goldring, Ayala ^b,e   Rienstein, Shlomit ^b   Friedman, Eitan ^b,e   Ben Baruch, Gilad ^d,e   Gotlieb, Walter H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^c UNIVERSITY OF MANITOBA   (Canada)

^d SHEBA MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EPITHELIUM TUMOR; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENCE RISK;

AGED; CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 64749097096     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.11.013     Document Type: Article

References (31)

1. Gajewski W., and Legare R.D. Ovarian cancer. Surg Oncol Clin N Am 7 (1998) 317-333
2. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L., Saigo P.E., Almadrones L.A., Barakat R.R., Brown C.L., Chi D.S., Curtin J.P., Poynor E.A., and Hoskins W.J. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283 (2000) 2260-2265
3. Thompson M.E., Jensen R.A., Obermiller P.S., Page D.L., and Holt J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9 (1995) 444-450
4. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., and Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
5. Canevari S., Gariboldi M., Reid J.F., Bongarzone I., and Pierotti M.A. Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol 60 (2006) 19-37
6. Morita K., Ono Y., Fukui H., Tomita S., Ueda Y., Terano A., and Fujimori T. Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors. Pathol Int 50 (2000) 219-223
7. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J.T., Dodge R., Clarke-Pearson D.L., Marks P., McKenzie S., Yin S., and Bast Jr. R.C. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50 (1990) 4087-4091
8. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix-Trench G., Thomas E.J., and Campbell I.G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58 (1998) 2095-2097
9. Riopel M.A., Spellerberg A., Griffin C.A., and Perlman E.J. Genetic analysis of ovarian germ cell tumors by comparative genomic hybridization. Cancer Res 58 (1998) 3105-3110
10. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., and Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21 (1999) 99-102
11. Shridhar V., Lee J., Pandita A., Iturria S., Avula R., Staub J., Morrissey M., Calhoun E., Sen A., Kalli K., Keeney G., Roche P., Cliby W., Lu K., Schmandt R., Mills G.B., Bast Jr. R.C., James C.D., Couch F.J., Hartmann L.C., Lillie J., and Smith D.I. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 61 (2001) 5895-5904
12. Sonoda G., Palazzo J., du Manoir S., Godwin A.K., Feder M., Yakushiji M., and Testa J.R. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer 20 (1997) 320-328
13. Suehiro Y., Sakamoto M., Umayahara K., Iwabuchi H., Sakamoto H., Tanaka N., Takeshima N., Yamauchi K., Hasumi K., Akiya T., Sakunaga H., Muroya T., Numa F., Kato H., Tenjin Y., and Sugishita T. Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 59 (2000) 50-56
14. Wasenius V.M., Jekunen A., Monni O., Joensuu H., Aebi S., Howell S.B., and Knuutila S. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer 18 (1997) 286-291
15. Wolf N.G., Abdul-Karim F.W., Farver C., Schröck E., du Manoir S., and Schwartz S. Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 25 (1999) 307-315
16. DeRisi J., Penland L., Brown P.O., Bittner M.L., Meltzer P.S., Ray M., Chen Y., Su Y.A., and Trent J.M. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14 (1996) 457-460
17. Kallioniemi A., Kallioniemi O.P., Sudar D., Rutovitz D., Gray J.W., Waldman F., and Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258 (1992) 818-821
18. Kudoh K., Takano M., Koshikawa T., Hirai M., Yoshida S., Mano Y., Yamamoto K., Ishii K., Kita T., Kikuchi Y., Nagata I., Miwa M., and Uchida K. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res 5 (1999) 2526-2531
19. Israeli O., Gotlieb W.H., Friedman E., Goldman B., Ben-Baruch G., Aviram-Goldring A., and Rienstein S. Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH. Gynecol Oncol 90 (2003) 629-636
20. Abeliovich D., Kaduri L., Lerer I., Weinberg N., Amir G., Sagi M., Zlotogora J., Heching N., and Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60 (1997) 505-514
21. Rohlfs E.M., Learning W.G., Friedman K.J., Couch F.J., Weber B.L., and Silverman L.M. Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43 (1997) 24-29
22. Hu J., Khanna V., Jones M.W., and Surti U. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis. Gynecol Oncol 89 (2003) 369-375
23. Helou K., Padilla-Nash H., Wangsa D., Karlsson E., Osterberg L., Karlsson P., Ried T., and Knutsen T. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet Cytogenet 170 (2006) 1-8
24. Suzuki S., Moore D.H., Ginzinger D.G., Godfrey T.E., Barclay J., Powell B., Pinkel D., Zaloudek C., Lu K., Mills G., Berchuck A., and Gray J.W. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60 (2000) 5382-5385
25. Iwabuchi H., Sakamoto M., Sakunaga H., Ma Y.Y., Carcangiu M.L., Pinkel D., Yang-Feng T.L., and Gray J.W. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 55 (1995) 6172-6180
26. Kiechle M., Jacobsen A., Schwarz-Boeger U., Hedderich J., Pfisterer J., and Arnold N. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 91 (2001) 534-540
27. Israeli O., Gotlieb W.H., Friedman E., Korach J., Friedman E., Goldman B., Zeltser A., Ben-Baruch G., Rienstein S., and Aviram-Goldring A. Genomic analyses of primary and metastatic serous epithelial ovarian cancer. Cancer Genet Cytogenet 154 (2004) 16-21
28. Fishman A., Shalom-Paz E., Fejgin M., Gaber E., Altaras M., and Amiel A. Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization. Int J Gynecol Cancer 15 (2005) 261-266
29. Makhija S., Sit A., Edwards R., Aufman K., Weiss H., Kanbour-Shakir A., Gooding W., D'Angelo G., Ferrell R., Raja S., and Godfrey T.E. Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Gynecol Oncol 90 (2003) 3-9
30. Pal T., Permuth-Wey J., Betts J.A., Krischer J.P., Fiorica J., Arango H., LaPolla J., Hoffman M., Martino M.A., Wakeley K., Wilbanks G., Nicosia S., Cantor A., and Sutphen R. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104 (2005) 2807-2816
31. Chetrit A., Hirsh-Yechezkel G., Ben-David Y., Lubin F., Friedman E., and Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26 (2008) 20-25